Ping Chu, MD
Hematology & Oncology · Tomball, TXNPI 1316957368
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,312 of the $6,182 with a category attached, or 85.9%. It is spread thinly across 37 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,520 and has fallen 79.2% since, to $525 in 2024.
Across 264 payments — averaging $23.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$867
- Daiichi Sankyo Inc.$646
- Eisai Inc.$504
- Pfizer$416
- Amgen$401
- Rigel Pharmaceuticals, Inc.$303
- plus $3K from 31 others
What the payments were for
- Consulting fees$5258%
- Food & beverage$5,31286%
- Education$3446%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 35 | $867 |
| Daiichi Sankyo Inc. | 8 | $646 |
| Eisai Inc. | 23 | $504 |
| Pfizer | 23 | $416 |
| Amgen | 14 | $401 |
| Rigel Pharmaceuticals, Inc. | 7 | $303 |
| Merck | 15 | $297 |
| GSK | 6 | $219 |
| AbbVie | 6 | $205 |
| Bristol Myers Squibb | 11 | $189 |
| Novartis | 9 | $173 |
| Boehringer Ingelheim | 11 | $171 |
| Pharmacyclics LLC, An Abbvie Company | 6 | $164 |
| AstraZeneca(2 entities) | 9 | $146 |
| Astellas Pharma US Inc | 8 | $137 |
| EMD Serono, Inc. | 7 | $130 |
| Incyte Corporation | 8 | $128 |
| Exelixis Inc. | 7 | $120 |
| Lilly USA, LLC | 6 | $118 |
| Ipsen Biopharmaceuticals, Inc | 7 | $115 |
| Johnson & Johnson | 5 | $110 |
| Secura Bio, Inc. | 4 | $78 |
| Teva Pharmaceuticals USA, Inc. | 3 | $68 |
| Macrogenics, Inc. | 3 | $65 |
| Kyowa Kirin, Inc. | 4 | $59 |
| Genentech USA, Inc. | 3 | $44 |
| Pharmacosmos Therapeutics Inc. | 2 | $42 |
| Bayer | 2 | $42 |
| Myovant Sciences Inc. | 2 | $38 |
| Dendreon Pharmaceuticals LLC | 2 | $36 |
| Lexicon Pharmaceuticals, Inc. | 2 | $35 |
| Sirtex Medical Inc | 1 | $25 |
| Morphosys, US Inc. | 1 | $24 |
| Taiho Oncology, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Dova Pharmaceuticals | 1 | $15 |
| Sanofi | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,182 in reported general payments places this provider in the 60th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Tomball
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Asad DeanFort Worth$1.1M
- Habte YimerTyler$934K
- Edward PearsonDallas$900K
- Naval DaverHouston$853K
- Christopher MaiselDallas$713K
- Clifton LaymanEl Paso$645K
- Jorge Cortes-FrancoHouston$627K
- Timothy FenskeSan Antonio$626K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.